A Phase 1 interventional study of MYK-461 in Hypertrophic Cardiomyopathy, sponsored by MyoKardia, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-09-14.
Sponsored by MyoKardia, Inc. · Phase 1, Interventional, and Treatment
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose study in NYHA Class I, II, or III patient volunteers aged 18-65 years.
Exclusion Criteria:
Drug: MYK-461
Safety: Incidence of adverse events
Time frame: 28 Days
Determination of pharmacokinetics parameters as measured by Cmax
maximum concentration (Cmax)
Time frame: 28 Days
Determination of pharmacokinetics parameters as measured by Tmax
time of the maximum measured concentration (Tmax)
Time frame: 28 Days
Determination of pharmacokinetics parameters as measured by AUC
area under the concentration-time curve (AUC)
Time frame: 28 Days
Determination of pharmacokinetics parameters as measured by t1/2
half-life (t1/2)
Time frame: 28 Days
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MyoKardia, Inc.